Hypoxic microenvironment and hepatocellular carcinoma treatment

Ci-Ai Lin, Lin-Lin Chang, Hong Zhu, Qiao-Jun He, Bo Yang

Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China.

Correspondence to: Dr. Bo Yang, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 866# Yuhangtang Rd, Hangzhou 310058, Zhejiang, China. E-mail: yang924@zju.edu.cn; Dr. Qiao-Jun He, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 866# Yuhangtang Rd, Hangzhou 310058, Zhejiang, China. E-mail: qiaojunhe@zju.edu.cn


Received: 22 Mar 2018 First Decision: 17 May 2018 Revised: 9 Jun 2018 Accepted: 9 Jun 2018 Published: 29 Jun 2018

Science Editor: Guang-Wen Cao Copy Editor: Jun-Yao Li Production Editor: Huan-Liang Wu

Abstract

Hepatocellular carcinoma (HCC) is one of the most rapidly growing and prevalent cancers in the whole world. The characterized hypoxia region inside the HCC tumors has been recently found as the key driver of HCC malignance and treatment failure, leading to a variety of hypoxia-related biological consequences including angiogenesis, metastasis, metabolism deregulation and drug resistance, which ultimately resulted in treatment failure of HCC. This review will summarize the signaling pathways involved in hypoxia-mediated malignance of HCC and discuss current advances of hypoxia-targeted therapies.

Keywords: Hepatocellular carcinoma, anti-cancer drugs, hypoxia-targeting strategie

INTRODUCTION

Hepatocellular carcinoma (HCC) is the sixth most common cancer globally, with a high mortality of 5-year survival rate less than 10%\[1,2\]. There are various etiologies implicated in development of HCC, including infection of hepatitis B virus (HBV) or hepatitis C virus (HCV)\[3,4\], chronic infection, and alcohol consumption\[5\]. According to the Barcelona Clinic Liver Cancer (BCLC) staging, HCCs can be classified into five stages with each receiving different treatments\[1\]. Effective therapeutic options include liver resection and liver transplantation, ablation and chemoembolization\[1\]. However, for patients often diagnosed with advanced, unresectable or metastatic HCC, chemotherapeutic treatment would be the only option\[1\]. Yet, as reported, significant drug resistance in these patients ultimately resulted in treatment failure\[6\].
Hypoxia is a common phenomenon in the intratumor regions of HCC patients. Abnormal microvasculature and unrestrained proliferation of HCC cells lead to oxygen deficiency. Hypoxia is involved in multiple biological process of HCC and promotes tumor aggressiveness, chemoresistance and immunotherapy resistance. Consequently, the hypoxic microenvironment has been regarded as promising target for HCC treatments. Under hypoxia, hypoxia-induced factors (HIFs) would be stabilized to trigger the transactivation of a series of hypoxia-response genes which promote the malignance of HCC. Thus, the transcription factors HIFs have been regarded as master regulators of hypoxic microenvironment. In contrast, several lines of evidence also implicated the HIF-independent hypoxia responses. Taken together, the mechanisms in HCC progression under hypoxia are complicated and sophisticated. This review will summarize current research advances in hypoxia-mediated molecular mechanism, how hypoxia participates in the progression of HCC and the current intervention strategies targeting intratumor hypoxia of HCC.

HYPOXIA PLAYS CRITICAL ROLES IN THE PROGRESSION AND MALIGNANCE OF HCC

Due to the rapid-growing nature of HCC, increased numbers of cells consume increased amount of oxygen, and hypoxia exists in regions of the tumor that are far away from blood vessels. Through various signaling pathways, hypoxia further triggers a series of HCC transformation, mediating its angiogenesis, metastasis, metabolism deregulation and drug resistance. Hypoxia is a major cause of hypervasculature of HCC by inducing angiogenic factors to stimulate angiogenesis and support tumor growth. In addition, a variety of genes would be transactivated under hypoxia by HIFs or the other transcriptional factor and involved in multiple steps of HCC metastasis including epithelial-mesenchymal transition (EMT), invasion of the extracellular matrix, intravasation, extravasation, and secondary growth of the metastases. Besides, hypoxia-regulated glycolysis module also contributes to HCC progression. Recent study also indicates that hypoxia promotes the differentiation and expansion of immune-suppressive stromal cells, and remodels the metabolic landscape to support immune privilege. Therefore, hypoxia can reduce the effectiveness of cancer immunotherapy. Thus, hypoxia microenvironment is highly relevant in HCC development and extensively involved in the process of HCC progression.

MOLECULAR PATHWAYS INVOLVED IN HYPOXIC HCC MALIGNANCE

The complicated and sophisticated pathways underlying hypoxia have been extensively investigated, and HIFs are identified to play pivotal roles under hypoxia, which has attracted most attention in this field for the last decades. Yet recently, the findings on the HIFs-independent regulation of tumor angiogenesis and chemoresistance under hypoxic conditions have challenged this notion and raised the possibility that the other important signaling pathways may also participate and promote the progression and malignance of HCC. Accumulating evidence shows that Yes associate-Protein (YAP), matrix metalloproteinases (MMPs), high mobility group box 1 (HMGB1) and glucose metabolism enzymes are involved in hypoxia-mediated effects in HCC. The above key molecules would be activated as sensors of intratumoral oxygen tension, and trigger the subsequent activation of hypoxia-mediated process, thus may also be regarded as potential targets for HCC therapy.

HIFs-dependent pathways

HIF system is composed of α-subunits and β-subunits. Under normoxia, HIF1α is maintained at very low basal activities due to constitutive degradation. Prolyl hydroxylation of HIF1α by prolyl hydroxylase domain-containing proteins (PHD1, PHD2 and PHD3) induces its ubiquitination and proteasomal degradation by an E3 ligase, von Hippel-Lindau tumor suppressor protein (pVHL). Besides, asparaginyl hydroxylation of HIF1α by factor inhibiting HIF (FIH) interferes its interaction with transcriptional coactivators, CREB-binding protein (CBP) and p300. Under hypoxia, lacking sufficient oxygen, hydroxylation and proteasomal degradation of HIF1α are impaired. HIF1α is stabilized and then translocates into nucleus.
heterodimerizes with HIF1β and binds core hypoxia-response element [HRE, 5′-(A/G)CGTG-3′]21. Many HIF target genes play important roles in HCC proliferation, metabolism, angiogenesis, invasion and metastasis6.

Activation of Wnt/β-catenin pathway, PI3K/AKT pathway and SNAIL1 are involved in the epithelial mesenchymal transition (EMT), increasing HCC invasion and metastasis22,23. As reported, β-catenin can reinforce the transcriptional activity of HIF1α and consequently facilitate hypoxia-induced EMT24. And regulation of BCL9 expression by HIF1α may explain the crosstalk between Wnt/β-catenin signaling and hypoxia signaling pathways25. Besides, HIF1α activation can be regulated by PI3K/Akt pathway, and the activation of PI3K/Akt/HIF1α pathway mediates hypoxia-induced EMT and drug resistance26,27. HIF1α also promotes EMT through increasing SNAIL1 transcription in HCC cells under hypoxia28. Angiogenic factors like VEGF, bone morphogenetic protein 4 (BMP4) and stem cell factor (SCF) can enhance HCC angiogenesis29. VEGF has been well characterized as a direct target of HIF systems30, promoting endothelial cell proliferation and migration especially in areas of hypoxia31,32. Additionally, hypoxia-induced BMP4 expression is regulated by HIF1α33 and SCF expression is HIF2α-dependent34 to promote HCC angiogenesis and metastasis. Many glycolysis-related genes can be transcriptionally activated by HIF1α, such as phosphoglycerate kinase 1 (PGK1), hexokinase-2 (HK2), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and phosphofructokinase (PFK)6,16. It indicates that there is an increased glycolysis in the progression of hypoxia HCC to adapt to oxygen deficiency. HIF1α induces growth factors, including TGF-α and IGF-2, to promote cell proliferation and survival35. TGF-α/EGFR can be activated by HIF2α and contribute to sorafenib resistance in HCC cells35. Besides, HIF1α regulates the expression of MMPs to induce extracellular matrix degradation and tumor metastasis36. NKG2D is critical in directing NK cell responses against tumors. Yamada et al.37 show that hypoxia promotes downregulation of the NKG2D ligand MICA by tumor cells via a HIF1α-dependent mechanism. Under hypoxia and in the presence of TGF-β, CD4+ T cells upregulate Foxp3 through direct binding of HIF1 to Foxp3 promoter region, inducing Treg formation and immune tolerance38. Taken together, HIF system regulates hypoxic responses of HCC through diverse signaling pathways, and contributes to HCC progression and malignant process.

**HIFs-independent pathways**

**HMGB1 signaling pathways**

HMGB1 is a chromatin-binding nuclear damage associated molecular pattern39. Its release under hypoxic condition can induce an inflammatory response to promote invasion and metastasis in HCC cells. Under hypoxic, HMGB1 activates TLR4 and RAGE signaling pathways to induce caspase-1 activation. Caspase-1 subsequently mediates the cleavage and release of a series of pro-inflammatory cytokines (IL-1β and IL-18), which in turn promote cancer invasion and metastasis18,40. Moreover, recent studies suggest that HMGB1 can also translocate from the nucleus to the cytosol under hypoxia, and then bind to mtDNA released from damaged mitochondria39. Subsequent activation of TLR9 signaling pathway promotes HCC proliferation18,39, indicating a novel mechanism of the involvement of HMGB1 in HCC progression under hypoxia.

**Hippo-YAP pathways**

The Hippo pathway is a classical regulator of organ size and regeneration, and YAP is an important transcriptional co-factor locating at the downstream of Hippo pathway41,42. The activation of YAP promotes survival, chemoresistance, metastasis, and the other malignant properties of HCC43. It has been reported in recent studies that hypoxia induces nuclear translocation and activation of YAP in a HIF-independent way, and the subsequent activation of target genes promotes cell survival, resistance to SN38 and sorafenib in HCC17,43. Meanwhile, statins (the inhibitors of hydroxymethylglutaryl-CoA reductase) can suppress YAP target genes and overcome hypoxia-induced resistance to sorafenib44. Moreover, YAP could also contribute to liver tumorigenesis by inducing HIF1α-dependent aerobic glycolysis44. HMGB1 is relevant in this process by binding to GA-binding protein alpha (GABPa) to promote the expression of YAP44.
THERAPEUTIC STRATEGIES TARGETING HYPOXIA FOR HCC TREATMENT

Sorafenib is the only effective first-line drug for advanced HCC. However, hypoxia-induced chemoresistance to sorafenib leads to treatment failure. Hypoxia also confers resistance to various anticancer drugs in HCC cells, including etoposide, sorafenib, SN38, cisplatin and doxorubicin. As hypoxia induces tumor malignant transformation and plays an important role in resistance to radiotherapy and chemotherapy, target-hypoxia therapy is reasonable in HCC treatment. There are several approaches to target hypoxic microenvironment. One approach is to design hypoxia-activated bioreductive pro-drugs which would be activated by enzymatic reduction in hypoxic tissue; the other one is to target key molecules specifically activated in hypoxic cells, such as the most studied HIFs inhibitors. In addition, emerging new strategies such as oxygen supplement and vessel normalization were also developed to target the hypoxic cancers.

Bioreductive prodrugs

Bioreductive prodrugs generally share a common mechanism of activation. They are activated by enzymatic reduction in hypoxic tissue to form cytotoxins, resulting in hypoxia-selective cell killing.

OXY111A is a synthetic allosteric effector of hemoglobin-4 and promotes normoxia in hypoxic tumors. OXY111A has been tested in several cancer animal models, showing beneficial outcomes and low side effect profiles. It is also shown to prevent HIF1α stabilization as well as VEGF production. Tirapazamine (TPZ; SR4233) belongs to the aromatic N-oxide family and has been extensively evaluated. TPZ is reported to potentiate the antitumor efficacy of many anticancer drugs, becoming a promising compound in combination-therapy. In addition, TPZ can also sensitize HCC cells to topoisomerase I inhibitors via cooperative modulation of HIF1α. As a novel hypoxia-activated prodrug, Q6 arrests tumor growth in vivo through dual hypoxia-targeted regulatory mechanisms. Q6 exhibits potent antiproliferative efficacy and induces apoptosis in HCC under hypoxic. Besides, Q6 can induce attenuation of HIF1α expression through autophagy-dependent degradation pathway as well. Recent study suggests that Q6 induces G2-M arrest and apoptosis via poisoning topoisomerase II. Thus Q6 shows a more potent anti-proliferative effect than TPZ.

Drugs targeting hypoxia related molecules

As a curcumin analog, diphenyl difluoroketone (EF24) is an effective and promising anticancer compound. EF24 enhance the antitumor effects of sorafenib and overcomes sorafenib resistance through VHL (Von Hippel-Lindau tumor suppressor)-dependent HIF1α degradation and NF-κB inactivation. Generally, EF24 exerts its effects by inhibition of proliferation and induction of apoptosis. It is reported that EF24 induces G2/M arrest and apoptosis by increasing phosphatase and tensin homologue expression (PTEN) in ovarian cancer cells. Recently, EF24 has been shown to suppress invasion and migration of HCC cells in vitro via inhibiting the phosphorylation of src. A series of compounds targeting hypoxia HCC are on clinical trials, such as RO7070179 and EZN-2968, both of which are antisense oligonucleotide inhibitors of HIF1α. Other compounds like Bufalin (target inhibition of PI3K-AKT-mTOR activity), ENMD-1198 (a microtubule destabilizing agent) and Metformin (an established antidiabetic drug) are involved in the suppression HIF1α expression.

The other treatments

Hyperbaric oxygen (HBO) treatment can enhance the amount of dissolved oxygen in the plasma and increase O₂ delivery to the tissue oxygen, so it can be used to overcome hypoxia. Both recent and previous research studies have shown that HBO can be inhibitory and reduce cancer growth in some cancer types. Granowitz et al. show that HBO can inhibit benign and malignant human mammary epithelial cell proliferation. In another study, Cheng et al. engineered VNP20009 to express histidine-proline-rich glycoprotein (HPRG) under the control of a hypoxia-induced NirB promoter. HPRG has potent antiangiogenic and tumor vessel normalization properties. Attenuated Salmonella Typhimurium strain VNP20009 preferentially accumulates and replicates in hypoxic tumor regions. They found that VNP20009-
mediated targeted expression of HPRG (VNP-pNHPRG) can down-regulate the HIF1α-VEGF/Ang-2 signal pathway by altering the hypoxic tumor microenvironment.

**PERSPECTIVES**

Hypoxia is highly relevant in malignant transformation of HCC and activates complicated molecular and cellular pathways through HIF-dependent or independent mechanisms [Figure 1]. Hypoxia promotes angiogenesis, invasion, metastasis, proliferation, glycolysis, drug resistance, inflammation and immune evasion. Consequently, targeting hypoxia has been regarded as promising strategies for HCC treatment. Nonetheless, there is no clear clinical evidence of efficient outcome of anti-cancer treatment due to the HIF-inhibition or the treatment of bioreductive agents. In the field of hypoxia-related studies, several concerns still remain, which need to be fully elucidated in the near future, so as to improve the clinical outcome of HCC patients, particularly those displayed intratumor hypoxia:

1. Mechanism of hypoxia response is not fully elucidated, as some recent studies have reported HIF-independent regulation of hypoxia response. It requires further investigation to further unravel the signaling pathways and crosstalk involved in hypoxic cancer;
2. There's a lack of effective treatment for hypoxic cancer. The efficacy of the bioreductive prodrugs should be improved, probably by selecting clinical cancer patients by appropriate biomarkers. In addition, more targets specifically activated under hypoxia should the exploited to seek more promising therapeutic strategies;
3. There's a problem of heterogeneity. It still remains elusive whether different quantitative levels of hypoxia in the same tumor tissue will represent similar response to hypoxia-targeted therapy. In order to guarantee the effectiveness and preciseness of treatment, we can take into consideration of researches in the relationship between the quantitative hypoxia levels and drug response.

In summary, with more profound investigations on hypoxic microenvironment, highly efficient and highly selective interventions will be developed, which will ultimately benefit those HCC patients with severe intratumoural hypoxia.
AUTHORS’ CONTRIBUTIONS
Manuscript writing: Lin CA, Chang LL, Zhu H
Manuscript revising: He QJ, Yang B

AVAILABILITY OF DATA AND MATERIALS
Not applicable.

FINANCIAL SUPPORT AND SPONSORSHIP
This work was supported by the National Natural Science Foundation for Distinguished Young Scholar of China (No. 81625024).

CONFLICTS OF INTEREST
All authors declared that there are no conflicts of interest.

ETHICAL APPROVAL AND CONSENT TO PARTICIPATE
Not applicable.

CONSENT FOR PUBLICATION
Not applicable.

COPYRIGHT
© The Author(s) 2018.

REFERENCES
20. McNeill LA, Hewitson KS, Claridge TD, Seibelf JF, Horsfall LE, Schofield CJ. Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1)


